JP6494112B2 - アストリンとラプターの相互作用調節因子、及びその癌治療での用途 - Google Patents

アストリンとラプターの相互作用調節因子、及びその癌治療での用途 Download PDF

Info

Publication number
JP6494112B2
JP6494112B2 JP2015552068A JP2015552068A JP6494112B2 JP 6494112 B2 JP6494112 B2 JP 6494112B2 JP 2015552068 A JP2015552068 A JP 2015552068A JP 2015552068 A JP2015552068 A JP 2015552068A JP 6494112 B2 JP6494112 B2 JP 6494112B2
Authority
JP
Japan
Prior art keywords
astrin
raptor
cells
cell
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015552068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511822A5 (cg-RX-API-DMAC10.html
JP2016511822A (ja
Inventor
セディーク，カトリン
ホルツヴァルト，ビルギット
バウマイスター，ラルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Ludwigs Universität Freiburg
Original Assignee
Albert Ludwigs Universität Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Ludwigs Universität Freiburg filed Critical Albert Ludwigs Universität Freiburg
Publication of JP2016511822A publication Critical patent/JP2016511822A/ja
Publication of JP2016511822A5 publication Critical patent/JP2016511822A5/ja
Application granted granted Critical
Publication of JP6494112B2 publication Critical patent/JP6494112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015552068A 2013-01-11 2014-01-13 アストリンとラプターの相互作用調節因子、及びその癌治療での用途 Expired - Fee Related JP6494112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13151022.4 2013-01-11
EP13151022.4A EP2755027B1 (en) 2013-01-11 2013-01-11 Modulators of the interaction of astrin and raptor, and uses thereof in cancer therapy
PCT/EP2014/050460 WO2014108532A1 (en) 2013-01-11 2014-01-13 Modulators of the interaction of astrin and raptor, and uses thereof in cancer therapy

Publications (3)

Publication Number Publication Date
JP2016511822A JP2016511822A (ja) 2016-04-21
JP2016511822A5 JP2016511822A5 (cg-RX-API-DMAC10.html) 2017-02-23
JP6494112B2 true JP6494112B2 (ja) 2019-04-03

Family

ID=47563201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552068A Expired - Fee Related JP6494112B2 (ja) 2013-01-11 2014-01-13 アストリンとラプターの相互作用調節因子、及びその癌治療での用途

Country Status (5)

Country Link
US (1) US10041933B2 (cg-RX-API-DMAC10.html)
EP (1) EP2755027B1 (cg-RX-API-DMAC10.html)
JP (1) JP6494112B2 (cg-RX-API-DMAC10.html)
ES (1) ES2588778T3 (cg-RX-API-DMAC10.html)
WO (1) WO2014108532A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11237168B2 (en) * 2019-06-26 2022-02-01 St. Jude Children's Research Hospital Method for identifying modulators of G3BP activity
CN110476877A (zh) * 2019-08-15 2019-11-22 上海交通大学医学院附属瑞金医院 一种β细胞中特异性Raptor敲除同时GFP示踪的小鼠的制备方法
CN113125747B (zh) * 2021-03-15 2022-06-14 天津医科大学 一种isPLA-Seq的高通量检测蛋白质相互作用的方法和试剂盒及其应用

Also Published As

Publication number Publication date
US10041933B2 (en) 2018-08-07
EP2755027A1 (en) 2014-07-16
WO2014108532A1 (en) 2014-07-17
EP2755027B1 (en) 2016-06-01
HK1199930A1 (en) 2015-07-24
ES2588778T3 (es) 2016-11-04
US20150355166A1 (en) 2015-12-10
JP2016511822A (ja) 2016-04-21

Similar Documents

Publication Publication Date Title
Wang et al. DDRGK1 enhances osteosarcoma chemoresistance via inhibiting KEAP1‐mediated NRF2 ubiquitination
Zgajnar et al. Biological actions of the Hsp90-binding immunophilins FKBP51 and FKBP52
Keleg et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion
Zhang et al. USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1
Joe et al. Myocilin interacts with syntrophins and is member of dystrophin-associated protein complex
Chen et al. Bmi‐1‐RING1B prevents GATA4‐dependent senescence‐associated pathological cardiac hypertrophy by promoting autophagic degradation of GATA4
Gong et al. Steroid receptor coactivator‐1 enhances the stemness of glioblastoma by activating long noncoding RNA XIST/miR‐152/KLF4 pathway
Kim et al. sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways
Kim et al. RhoBTB3 regulates proliferation and invasion of breast cancer cells via Col1a1
Huang et al. Overexpressed ACBD3 has prognostic value in human breast cancer and promotes the self-renewal potential of breast cancer cells by activating the Wnt/beta-catenin signaling pathway
Seong et al. Zinc finger protein ZPR9 functions as an activator of AMPK-related serine/threonine kinase MPK38/MELK involved in ASK1/TGF-β/p53 signaling pathways
Xiao et al. USP39-mediated deubiquitination of Cyclin B1 promotes tumor cell proliferation and glioma progression
Lee et al. The E2F activators control multiple mitotic regulators and maintain genomic integrity through Sgo1 and BubR1
Sánchez‐Morgan et al. UXT Is a LOX‐PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells
Zhang et al. The CXXC finger 5 protein is required for DNA damage-induced p53 activation
Pandey et al. Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppression
Hong et al. Heterozygous PTCH1 mutations impact the bone metabolism in patients with nevoid basal cell carcinoma syndrome likely by regulating SPARC expression
Minai‑Tehrani et al. The O‑glycosylation mutant osteopontin alters lung cancer cell growth and migration in vitro and in vivo
Yang et al. Catenin delta-1 (CTNND1) phosphorylation controls the mesenchymal to epithelial transition in astrocytic tumors
Jang et al. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation
US10041933B2 (en) Modulators of the interaction of astrin and raptor, and uses thereof in cancer therapy
Wang et al. EMP2 acts as a suppressor of melanoma and is negatively regulated by mTOR-mediated autophagy
Yu et al. The casein kinase 2α promotes the occurrence polycystic ovary syndrome
Pan et al. Selenomethionine suppress the progression of poorly differentiated thyroid cancer via LncRNA NONMMUT014201/miR-6963-5p/srprb pathway
Cao et al. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190304

R150 Certificate of patent or registration of utility model

Ref document number: 6494112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees